glp 1 for alcohol use disorder A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used weight loss, such as semaglutide, may also help reduce heavy drinking in individuals GLP-1 Drug Semaglutide Substantially Reduced

Research demonstrates that approximately one-third of patients lose less than 0.5% body weight weekly during the first month of intensive behavioral treatment, with the majority of these individuals ultimately failing to achieve clinically meaningful results after six months

Its also necessary for healthy immune function and general antioxidant defenses against free radicals

No trial has followed patients long enough after stopping to answer this

P = .044) on univariate analysis, but the rate was no longer significantly different on multivariate analysis

However, it is possible this may have occurred since this group was eating less at week 8 than at baseline regarding kcal/kg and protein/kg